Genetic Testing in Men With Metastatic Castration-Resistant Prostate Cancer

Pedro C Barata; Jonathan Assayag; Benjamin Li; Gordon Siu; Alexander Niyazov

doi:10.1001/jamaoncol.2024.0851

Genetic Testing in Men With Metastatic Castration-Resistant Prostate Cancer

JAMA Oncol. 2024 Jul 1;10(7):975-977. doi: 10.1001/jamaoncol.2024.0851.

Authors

Pedro C Barata¹, Jonathan Assayag², Benjamin Li³, Gordon Siu³, Alexander Niyazov³

Affiliations

¹ University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio.
² Pfizer Inc, Kirkland, Quebec, Canada.
³ Pfizer Inc, New York, New York.

No abstract available

Plain language summary

This cross-sectional study assesses homologous recombination repair mutation genetic testing and associated characteristics among men with metastatic castration-resistant prostate cancer (mCRPC).

MeSH terms

Genetic Testing*
Humans
Male
Neoplasm Metastasis*
Prostatic Neoplasms, Castration-Resistant* / drug therapy
Prostatic Neoplasms, Castration-Resistant* / genetics
Prostatic Neoplasms, Castration-Resistant* / pathology